Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Angela D. Motter(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
January 1, 2022
10.6004/jnccn.2022.0001
Cited by 645

Related Papers

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
|Journal of Clinical Oncology|2013|443
Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors
|Journal of Clinical Oncology|2007|351
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
|The Lancet Oncology|2016|219